Rüdiger Hehlmann

发表

Julian Varghese, Martin Dugas, Christian Holz, 2016, MIE.

Zinc protoporphyrin, a useful parameter to address hyperferritinemia

Rüdiger Hehlmann, R. Hehlmann, A. Dorn-Beineke, 2007, Annals of Hematology.

In chronic myeloid leukemia white cells from cytogenetic responders and non-responders to imatinib have very similar gene expression signatures.

Yi-Ching Hsieh, Knut Krohn, Andreas Hochhaus, 2005, Haematologica.

European LeukemiaNet recommendations for the management of chronic myeloid leukemia: 2013.

Francisco Cervantes, Simona Soverini, Giovanni Martinelli, 2013, Blood.

Chronic myeloid leukaemia

Andreas Hochhaus, Rüdiger Hehlmann, M. Baccarani, 2007, The Lancet.

Chronic myelogenous leukemia: molecular and cellular aspects

Andreas Hochhaus, Rüdiger Hehlmann, R. Hehlmann, 1998, Journal of Cancer Research and Clinical Oncology.

Tolerability-adapted imatinib 800 mg/d versus 400 mg/d versus 400 mg/d plus interferon-α in newly diagnosed chronic myeloid leukemia.

Stefan W Krause, Alois Gratwohl, Claudia Haferlach, 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Monitoring CML patients responding to treatment with tyrosine kinase inhibitors: review and recommendations for harmonizing current methodology for detecting BCR-ABL transcripts and kinase domain mutations and for expressing results.

Simona Soverini, Giovanni Martinelli, Susan Branford, 2006, Blood.

Assessment of retroviral activity using a universal retrovirus chip.

Rüdiger Hehlmann, R. Hehlmann, C. Speth, 2003, Journal of virological methods.

Analysis and validation of prognostic factors for CML

Joerg Hasford, Rüdiger Hehlmann, J. Hasford, 1996 .